Tricyclic Antidepressants and Monoamine Oxidase Inhibitors

Combined treatment with MAO-A inhibitor and MAO-B inhibitor increases extracellular noradrenaline levels more than MAO-A inhibitor alone through increases in β-phenylethylamine

“…However, irreversible MAO inhibitors entail risks of causing hypertensive attacks after consumption of tyramine-rich food (Blackwell et al, 1967) and of causing serotonin syndrome in cases of co-administration of non-selective MAO inhibitors and tricyclic antidepressants (TCA) or selective serotonin reuptake inhibitors (SSRIs) (Schuckit et al, 1971;Ananth and Luchins, 1977;Sternbach, 1991).…”

Clinically relevant drug interactions between anticancer drugs and psychotropic agents

“…Procarbazine is an ACD which possesses weak MAO inhibitor activity (Massoud et al 2004). Thus, concomitant use of this ACD with tricyclic antidepressants (TCAs) (Sjöqvist 1965;Schuckit et al 1971;White & Simpson 1984;Neuvonen et al 1993), selective serotonin reuptake inhibitors (SSRIs) (Feighner et al 1990;Sternbach 1991;Coplan & Gorman 1993;Neuvonen et al 1993;Graber et al 1994;Lappin & Auchincloss 1994;Clark et al 2006;Eli Lilly and Company 2008) and serotonin/norepinephrine reuptake inhibitors (Hodgman et al 1997;Sweetman 2002) can lead to an increased risk of CNS toxicity or serotonin syndrome, which is characterised by mental state changes, myoclonus, hyperthermia and autonomic instability. In addition, this DDI is also expected with atomoxetine, mirtazepine and moclobemide (Sweetman 2002;Eli Lilly and Company 2007;Organon USA 2007).…”

Tricyclics and newer antidepressant medications: Treatment options for treatment‐resistant depressions

“…Nevertheless, a number of case reports and open label series from the 1960s (Sargant, 1963;Gander, 1965;Dally, 1965), 1970s (Ray, 1973;Winston, 1971;Schuckit et al, 1971;Sethna, 1974;Spiker and Pugh, 1976), and 1980s (Schmauss et al, 1986(Schmauss et al, , 1988 suggest that these agents may be synergistically effective, when used in combination (Table 5). Nevertheless, a number of case reports and open label series from the 1960s (Sargant, 1963;Gander, 1965;Dally, 1965), 1970s (Ray, 1973;Winston, 1971;Schuckit et al, 1971;Sethna, 1974;Spiker and Pugh, 1976), and 1980s (Schmauss et al, 1986(Schmauss et al, , 1988 suggest that these agents may be synergistically effective, when used in combination (Table 5).…”

“…The combined use of TCAs and MAOIs violates an explicit prohibition against their concurrent use in the Physician's Desk Reference. Nevertheless, a number of case reports and open label series from the 1960s (Sargant, 1963;Gander, 1965;Dally, 1965), 1970s (Ray, 1973;Winston, 1971;Schuckit et al, 1971;Sethna, 1974;Spiker and Pugh, 1976), and 1980s (Schmauss et al, 1986(Schmauss et al, , 1988 suggest that these agents may be synergistically effective, when used in combination (Table 5). The safety of this TCA-MA01 combination has been demonstrated in two controlled trials in nonresistant depressed patients (Razani et al, 1983;Young et al, 1979).…”